InvestSMART

Argent Biopharma Limited (ASX:RGT)

ALERT: Price-sensitive ASX Announcement for RGT
Current share price for RGT : $0.032 -0.024 (-42.86%)+
Announcement
Release
30 Jan 2026 8:15AM
Price at Release
$0.056
Full Release
download
Summary
Argent BioPharma Limited reported its quarterly activities and cash flow for the quarter ending 31 December 2025. The company announced a strategic acquisition of AusCann assets to strengthen its clinical pipeline and intellectual property, focusing on the CannEpil product. Argent agreed to acquire a 48% equity interest in CannPal Animal Therapeutics Pty Ltd from AusCann Group Holdings Ltd, pending shareholder approval. The company also secured a funding facility of up to A$11,000,000 from US-based investment funds, including an immediate A$3,000,000 drawdown to support operations and the AusCann acquisition. The quarterly cash flow report indicated operational outflows of A$1,553k, primarily due to staff and R&D costs. Argent concluded the quarter with A$1,529k in cash and cash equivalents, and an unused finance facility of A$15,652k.
Key Points
  • Argent BioPharma announced a strategic acquisition of AusCann assets.
  • The company aims to strengthen its clinical pipeline and intellectual property.
  • Argent secured a funding facility of up to A$11,000,000.
  • Operational outflows totaled A$1,553k for the quarter.
  • The transaction with AusCann involves acquiring 48% equity in CannPal.
  • Completion of the acquisition is expected in Q1 2026, subject to shareholder approval.
  • The company concluded the quarter with A$1,529k in cash and A$15,652k in unused facilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.